

GeneMatrix Unveils Global HQ at Fulton Labs, Accelerating AI-Powered Precision Medicine & Genomic Innovation

Fulton Labs HQ unites AI, advanced genomics, and CAP-accredited labs to speed personalized medicine breakthroughs worldwide.

CHICAGO, IL, UNITED STATES, June 11, 2025 /EINPresswire.com/ -- GeneMatrix, a world leader in genomics and artificial intelligence-powered preventive health, has officially opened its new global headquarters at Fulton Labs, 1375 W Fulton St, Suite 545, Chicago, IL 60607. The purpose-built facility cements GeneMatrix's role at the forefront of precision medicine and launches [GeneCancer™](#), a 108-gene hereditary cancer test that delivers clinically actionable insights in just seven days.

“

Our new Fulton Labs HQ lets us fuse AI and genomics under one roof, accelerating breakthroughs that help people predict and prevent disease—not react to it.”

Tarek Younis

“Fulton Labs isn’t just our new address—it’s a launchpad for life science breakthroughs,” said Tarek Younis, Founder & CEO of GeneMatrix. “With this headquarters and GeneCancer at its heart, we’re scaling AI-driven genomics so every patient can anticipate, prevent, and beat disease long before symptoms appear.”

Why Fulton Labs & Fulton Market

Situated amid Chicago’s thriving Fulton Market District, Fulton Labs is a 16-story, 425,000-sq-ft life sciences tower engineered for next-generation research:

GMP, CLIA, and CAP-ready infrastructure with vibration-isolated wet and dry labs

Redundant mechanical systems that guarantee uninterrupted sequencing and AI workloads

LEED-certified design for lower carbon footprint and reduced operating costs

Collaboration lounges, innovation galleries, and skyline rooftop that foster partnerships across academia, venture capital, and global biotech anchors

This ecosystem positions GeneMatrix to accelerate R&D, automate its AI genomics platform, and recruit the top talent driving Chicago's rise as a biomedical powerhouse.

Inside the New HQ

AI + Genomics Engine – Unified data lake integrates high-throughput sequencers, robotic liquid handlers, and GPU clusters for real-time variant interpretation.

PopulationHealth Command Center – Cloud dashboards monitor anonymized genomic trends, enabling national precision health programs with partner ministries.

Innovation Studio – Flexible space for co-development with health system CIOs, payers, and start-ups tackling medication safety, chronic disease prediction, and nutrition.

Event & Training Hub – On-site auditorium and simulation labs host CME-accredited pharmacogenomics workshops and community STEM programs.

Introducing GeneCancer™

Building on its flagship GenePGx pharmacogenomics panel, GeneMatrix's new GeneCancer™ test screens 108 high-penetrance genes—including BRCA1/2, TP53, MLH1, and PALB2—covering breast, ovarian, colorectal, pancreatic, and rarer cancers. Key differentiators:

Seven-Day Turnaround — Industry-leading speed from sample receipt to oncologist-ready report

AI-Prioritized Variants — Machine-learning triage flags category 1 & 2 variants for expedited counseling

Actionable Pathways — Matches risk profiles with NCCN-aligned surveillance and prophylactic surgery options

Privacy by Design — Samples destroyed within 90 days; data never sold or used for non-medical advertising



The graphic features the GeneMatrix logo at the top, consisting of the word 'GENE' in black, a stylized purple and blue diamond icon, and the word 'MATRIX' in black. Below the logo, the title 'GLOBAL REACH, LOCAL IMPACT' is displayed in large, bold, black capital letters. Underneath the title, a subtitle reads: 'Serving communities in the U.S., Europe, MENA, LATAM, and Asia—making precision health universal.' The central visual is a globe with a blue and purple color scheme, overlaid with a network of white lines and nodes representing global connectivity. The globe is set against a background of soft, overlapping purple and blue shapes.

GeneMatrix graphic showcasing a connected globe to highlight the company's global reach and local impact in precision health.

“Every hour counts when it comes to cancer prevention,” noted Dr. Melissa Gomez, MD, clinical pharmacologist and external advisor. “GeneCancer’s rapid, comprehensive approach empowers clinicians to shift from reactive treatment to truly proactive care.”

Delivering the Future of Medicine

GeneMatrix now offers 12+ DNA panels that integrate seamlessly into electronic health record systems:

Panel Focus Key Benefit

GenePGx Pharmacogenomics Reduces adverse drug reactions, optimizes dosing

GeneDiet & GeneSport Nutrigenomics Personalizes diet, fitness, and supplement plans

GeneMind Mental health pharmacogenomics Guides antidepressant and antipsychotic selection

GeneResilience Stress & immunity Identifies variants tied to burnout and recovery

GeneCancer™ Hereditary oncology Enables early detection and targeted surveillance

All results are delivered through a HIPAA-compliant cloud portal, translating complex genomics into clear, color-coded guidance for clinicians and consumers alike.

A Launchpad for Global Impact

The Fulton Labs HQ will fuel GeneMatrix’s expanding footprint across Europe, the Gulf, LATAM, and North America. Active initiatives include:

National Genomic Screening – Population-scale partnerships aimed at reducing preventable disease burden.

Hospital AI Plug-Ins – Real-time drug-gene alerts embedded in EHR workflows, slashing medication-error costs.

Workplace Wellness – Employer programs leveraging GeneDiet and GenePGx to cut absenteeism and boost productivity.

“This headquarters turns vision into velocity,” Younis added. “With world-class infrastructure and a growing global partner network, we can deliver AI-enabled precision medicine to millions—faster than ever.”

About GeneMatrix LLC

GeneMatrix is a U.S. biotechnology company pioneering [AI-driven genomics and precision health](#). By combining DNA-based diagnostics, pharmacogenomics, and advanced analytics, GeneMatrix helps healthcare providers, governments, and consumers on five continents predict, treat, and prevent disease with unprecedented accuracy.

Media Contact

Tarek Younis, Founder & CEO
1375 W Fulton St, Suite 545, Chicago, IL 60607
tarek@genematrix.io
www.genematrix.io

Tarek Younis
Gene Matrix
+1 8473029668
[email us here](#)
Visit us on social media:
[LinkedIn](#)
[Instagram](#)
[Facebook](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/821244790>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.